In non-cardioembolic ischemic stroke^ should we treat with two anti-platelet agents (like adding dipyridamole or clopidogrel to ASA) or just one?
Evidence supports using single agent (ASA or clopidogrel) after stroke or transient ischemic attack. Some evidence favours combined dipyridamole and ASA (DP-ASA^ Aggrenox®) but new results question this benefit.
*** Original Documents can be found and downloaded using the link provided below ***
Publication Date: 2014-3-17
Last Updated on PCR: 2017-03-31 14:29:18